GILD

GILD

Gilead Sciences Inc. Common Stock

$112.050+-0.000 (-0.000%)

Preço em tempo real

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$112.050

Máximo

$112.050

Mínimo

$112.050

Volume

6.41M

Fundamentos da empresa

Estatísticas de negociação

Notícias relacionadas

Reuters

US FDA places clinical hold on Gilead trials testing HIV pill combination

The U.S. Food and Drug Administration has placed a clinical hold on Gilead Sciences' trials testing a combination of two of its experimental HIV treatments, the company said on Tuesday.

Ver mais
US FDA places clinical hold on Gilead trials testing HIV pill combination
CNBC

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.

Ver mais
Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO
BusinessWire

ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors

– Second Positive Phase 3 Trial in First-line Metastatic TNBC Where Trodelvy Has Demonstrated a Clinically Meaningful Benefit Versus Standard of Care Chemotherapy – – Trodelvy Has the Potential to Be the Backbone of

Ver mais
ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors

Mantenha-se atualizado

Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.